Felix Biotechnology, a biotechnology company focused on developing first-in-class, accessible, antibacterial therapies to treat drug-resistant infections, has signed a partnership with AnimalBiome, a leader in pet health and wellness, to develop new solutions to address diarrhea in pets.
There is a growing need for chemical-free and safe antimicrobial solutions that selectively remove problematic bacteria while preserving the beneficial bacteria of the microbiome. Felix’s platform can be leveraged against a broad range of problem bacterial species. The company has several on-going partnerships to develop phage-based solutions with personal care and cosmetic companies, and this deal expands their footprint into animal health.
Bacteriophage or phage, are tiny viruses that infect and kill bacteria. By combining machine learning and synthetic biology, Felix engineers phage to overcome the main hurdles facing the broad adoption of phage technologies today: narrow spectrum and phage resistance.
“We are committed to finding a better solution for this common affliction plaguing pets and distressing their owners,” said Dr. Natalie Ma, Felix Cofounder and Head of BD at Felix. “Through our unique approach to phage technologies, we will create a safe, chemical-free, durable and effective treatment for this pernicious pathogen.”
“At AnimalBiome, we are focused on providing new microbiome-focused solutions to help pets and their owners. Phage technology offers great promise in reducing the use of antibiotics in the treatment of bacterial pathogens, protecting beneficial microbes and supporting better health and wellness,” said Dr. Holly Ganz, CSO of AnimalBiome. “We are excited to work with Felix to develop new products specifically designed for pathogens afflicting companion animals.”